ResMed (RMD) has been a commendable growth stock, with its Q3 earnings surpassing estimates and leading to increased valuation. The stock has been robust amid market fluctuations, outperforming the market multiple times. There has been a notable swing in investor sentiment with
Norden Group and
Mediolanum International Funds Ltd acquiring new shares, despite sell-offs by
Illinois Municipal Retirement Fund and
Mutual of America Capital Management LLC. Eli Lilly's clinical trials led to a temporary drop in ResMed's stock, but it recovered quickly, a testament to its resilience. Notable insider transactions were by CFO, Brett Sandercock, selling significant shares, and CEO, Michael J. Farrell, also conducted substantial share sales. The impact of Eli Lilly's weight loss drug on ResMed stock did not deeply affect the bullish stance of analysts. Looking forward, ResMed is expected to release Q4 earnings on August 1, 2024. ResMed's new AirCurve 11 device, aimed at treating sleep apnea, could potentially spur increased demand. Additionally, investor popularity for the company has remained sturdy despite economic turbulence.
Resmed RMD News Analytics from Tue, 12 Dec 2023 08:00:00 GMT to Sun, 14 Jul 2024 16:44:01 GMT -
Rating 7
- Innovation 2
- Information 6
- Rumor 4
